Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office declined to institute an inter partes review of a patent owned by Biogen.   3 September 2015
Americas
Congress has apparently taken note of the strategy of hedge fund manager Kyle Bass to take advantage of the IPR process, with two pending patent reform bills which include provisions that could curtail his activities, says John Abramic of Steptoe & Johnson.   3 September 2015
Americas
A group of 23 law professors has urged the US Court of Appeals for the Federal Circuit to re-hear the Ariosa v Sequenom dispute en banc.   2 September 2015
Americas
Hedge fund manager Kyle Bass’s group the Coalition for Affordable Drugs has targeted two patents owned by the University of Pennsylvania in the latest petition for an inter partes review.   1 September 2015
Americas
The US Food and Drug Administration has proposed using four-letter suffixes to name biosimilar drugs.   1 September 2015
Americas
US pharmaceutical company Eli Lilly has thwarted attempts by its competitors to market a generic version of its Alimta (pemetrexed) drug.   27 August 2015
Big Pharma
The competence in various areas of the new Unified Patent Court is a matter of conjecture, as Paul England and Christof Höhne of law firm Taylor Wessing report.   27 August 2015
Americas
Pfizer’s buyout of Hospira, which is set to boost Pfizer’s biosimilars portfolio but has been the subject of anti-competition concerns, will be completed next month after gaining final approval.   26 August 2015
Americas
Hedge fund manager Kyle Bass has been dealt a blow after failing to invalidate two patents owned by biotechnology company Acorda Therapeutics.   25 August 2015
Americas
Sandoz, Allergan and Accord Healthcare have demonstrated “clear and convincing” evidence that a patent owned by Millennium Pharmaceuticals and used in its Velcade cancer treatment drug is invalid, according to a US court ruling.   24 August 2015